

Endocan and Erectile Dysfunction

American Journal of Men's Health
November-December 2019: 1–2
© The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1557988319893889
journals.sagepub.com/home/jmh



Sevket Balta¹  and Dimitri P. Mikhailidis²

Abstract

Endothelial dysfunction (ED) occurs early in the development of atherosclerosis. Predictors of vascular risk including obesity, hyperlipidemia, metabolic syndrome, diabetes mellitus, and hypertension are associated with both vascular endothelial and ED. Endocan is a novel marker of endothelial dysfunction, inflammation, and atherosclerosis. Raised endocan levels (usually measured by ELISA assays) were reported in some cardiovascular diseases and related conditions. Increased endocan levels may represent the endothelial and inflammatory components of the pathogenesis of ED and may, therefore, prove useful in clinical practice.

Keywords

Inflammation, endothelial dysfunction, sexuality

Received September 18, 2019; revised November 16, 2019; accepted November 18, 2019

Endocan and Erectile Dysfunction

Predictors of vascular risk including obesity, hyperlipidemia, metabolic syndrome, diabetes mellitus, and hypertension are associated with the presence of erectile dysfunction (ED) and vascular endothelial dysfunction (Elzanaty et al., 2016). Endothelial injury, inflammation, and dysfunction play a role in the pathogenesis of ED (Zhao et al., 2018).

Endocan is a novel immunoinflammatory marker (Balta et al., 2015) and elevated levels were reported in some endothelial dysfunction-related diseases (Balta et al., 2013, 2014; Celik et al., 2014; Icli et al., 2015).

There is evidence of an association between several inflammatory diseases and endocan (Balta et al., 2015). In this context, endocan was a strong predictor of overall and cardiovascular mortality in patients with inflammatory conditions (Yilmaz et al., 2014). In agreement with previous studies, patients with Behçet's disease had significantly higher serum levels of endocan (Balta et al., 2014). Serum endocan levels correlated positively with established inflammatory markers (e.g., C-reactive protein (CRP), erythrocyte sedimentation rate, and disease activity) in these patients (Balta et al., 2014). Similarly, Balta et al. (2013) showed that endocan levels were higher in patients with psoriasis vulgaris compared with controls; again, there was a correlation with indices of inflammation (e.g., CRP and Psoriasis Area and Severity Index).

Demirkol et al. (2014) investigated the relation between cardiac syndrome X (CSX; a condition where coronary endothelial dysfunction can cause angina pectoris) and ED. They compared CSX patients and controls using the International Index of Erectile Function Questionnaire (IIEF)-5. They showed that the IIEF-5 scores in the CSX group were significantly lower than those of control group (Demirkol et al., 2014). In addition, previous studies showed that increased levels of some biomarkers can reflect inflammation, angiogenesis, coagulation, tumor invasion, and degenerative changes in vascular endothelial cells (Balta et al., 2015). In this context, CRP, a well-established inflammatory biomarker is strongly, independently associated with the ED (Li et al., 2019). Onuk et al. (2018) classified the ED patients (as severe, moderate, or mild) using the Sexual Health Inventory for Men (SHIM) questionnaire. They reported a significant difference in serum endocan levels between the severe ED and the control group. Also, a significant negative correlation between the SHIM score and

¹Department of Cardiology, Hayat Hospital, Malatya, Turkey

²Department of Clinical Chemistry, Medical School London, University College London (UCL), London, UK

Corresponding Author:

Sevket Balta, Department of Cardiology, Hayat Hospital, Kışla St., Battalgazi, Malatya 04400, Turkey.
Emails: drsevketb@gmail.com, drsevketb@yahoo.com.tr



endocan levels was observed. This study defined the presence of an association between plasma endocan levels and ED.

Elkamshoushi et al. (2018) investigated the relation between ED and endocan levels. ED (defined by the IIEF-5 score) negatively correlated with endocan levels. These authors proposed that endocan levels can correlate with the severity of ED.

Karabakan et al. (2017) compared ED patients and controls by using the IIEF-5 score. They reported higher endocan levels in ED patients compared with controls. Also, endocan levels correlated with the severity of ED (Karabakan et al., 2017).

Significant differences between control and ED groups in terms of the serum endocan levels may prove useful in the evaluation of endothelial dysfunction in these patients. Atherosclerosis and ED share similar risk factors/predictors (Katsiki et al., 2015). It is therefore expected that these two conditions share other markers (e.g., endocan).

In conclusion, increased endocan levels may represent the endothelial and inflammatory components of the pathogenesis of ED. Endocan may prove to be useful as a novel diagnostic marker for the severity of ED. Further studies are needed to evaluate these associations.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Sevket Balta  <https://orcid.org/0000-0002-6657-7334>

References

- Balta, I., Balta, S., Demirkol, S., Mikhailidis, D. P., Celik, T., Akhan, M., Kurt, O., Kurt, Y. G., Aydin, I., & Kilic, S. (2013). Elevated serum levels of endocan in patients with psoriasis vulgaris: Correlations with cardiovascular risk and activity of disease. *British Journal of Dermatology*, *169*(5), 1066–1070.
- Balta, I., Balta, S., Koryurek, O. M., Demirkol, S., Mikhailidis, D. P., Celik, T., Cakar, M., Kucuk, U., Eksioglu, M., & Kurt, Y. G. (2014). Serum endocan levels as a marker of disease activity in patients with Behçet disease. *Journal of the American Academy of Dermatology*, *70*(2), 291–296.
- Balta, S., Mikhailidis, D. P., Demirkol, S., Ozturk, C., Celik, T., & Iyisooy, A. (2015). Endocan: A novel inflammatory indicator in cardiovascular disease? *Atherosclerosis*, *243*(1), 339–343.
- Celik, T., Balta, S., Karaman, M., Ahmet Ay, S., Demirkol, S., Ozturk, C., Dinc, M., Unal, H. U., Yilmaz, M. I., Kilic, S., Kurt, G., Tas, A., Iyisooy, A., Quarti-Trevano, F., Fici, F., & Grassi, G. (2014). Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan. *Blood Press*, *24*(1), 55–60.
- Demirkol, S., Balta, S., Kucuk, U., Celik, T., Arslan, Z., Olgun Kucuk, H., Unlu, M., Cagdas Yuksel, U., Samedli, S., Yokusoglu, M., Iyisooy, A., & Kursaklioglu, H. (2014). Association between microvascular angina and erectile dysfunction. *International Journal of Impotence Research*, *26*(4), 124–127.
- Elkamshoushi, A. A. M., Hassan, E. M., El Abd, A. M., Hassan, S. Z., & Maher, A. A. (2018). Serum endocan as a predictive biomarker of cardiovascular risk in erectile dysfunction patients. *Andrologia*, *50*(10), e13113.
- Elzanaty, S., Rezaezhad, B., Willenheimer, R., & Borgquist, R. (2016). Association between erectile function and biomarkers of subclinical atherosclerosis: A study based on middle-aged healthy men from the general population. *Current Urology*, *9*(3), 119–123.
- Icli, A., Cure, E., Cure, M. C., Uslu, A. U., Balta, S., Mikhailidis, D. P., Ozturk, C., Arslan, S., Sakız, D., Sahin, M., & Kucuk, A. (2015). Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. *Angiology*, *67*(8), 749–755.
- Karabakan, M., Bozkurt, A., Akdemir, S., Gunay, M., & Keskin, E. (2017). Significance of serum endothelial cell specific molecule-1 (Endocan) level in patients with erectile dysfunction: A pilot study. *International Journal of Impotence Research*, *29*(4), 175–178.
- Katsiki, N., Wierzbicki, A. S., & Mikhailidis, D. P. (2015). Erectile dysfunction and coronary heart disease. *Current Opinion in Cardiology*, *30*(4), 416–421.
- Li, W., Chen, K., Zhang, J., Wang, X., Xu, G., Zhu, Y., & Lv, Y. (2019). Association between serum high-sensitivity C-reactive protein levels and erectile dysfunction: A cross-sectional study of Chinese male population. *Scientific Reports*, *9*(1), 5929.
- Onuk, Ö., Arslan, B., Gezmis, T. C., Çetin, B., Göv, T., Yazıcı, G., Gürkan, O., & Ozdemir, E. (2018). Is the plasma endocan level a reliable predictor for the severity of erectile dysfunction? *International Urology and Nephrology*, *50*(9), 1577–1582.
- Yilmaz, M. I., Sırıopol, D., Saglam, M., Kurt, Y. G., Unal, H. U., Eyileten, T., Gok, M., Cetinkaya, H., Oguz, Y., Sari, S., Vural, A., Mititiuc, I., Covic, A., & Kanbay, M. (2014). Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. *Kidney International*, *86*(6), 1213–1220.
- Zhao, T., Kecheng, Y., Zhao, X., Hu, X., Zhu, J., Wang, Y., & Ni, J. (2018). The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease. *Medicine*, *97*(49), e13407.